+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Attomole detection of 3H in biological samples using accelerator mass spectrometry: application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry



Attomole detection of 3H in biological samples using accelerator mass spectrometry: application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry



Chemical Research in Toxicology 11(10): 1217-1222



This is the first demonstration of the use of accelerator mass spectrometry (AMS) as a tool for the measurement of 3H with attomole (10(-18) mol) sensitivity in a biological study. AMS is an analytical technique for quantifying rare isotopes with high sensitivity and precision and has been most commonly used to measure 14C in both the geosciences and more recently in biomedical research. AMS measurement of serially diluted samples containing a 3H-labeled tracer showed a strong correlation with liquid scintillation counting. The mean coefficient of variation of 3H AMS based upon the analysis of separately prepared aliquots of these samples was 12%. The sensitivity for 3H detection in tissue, protein, and DNA was approximately 2-4 amol/mg of sample. This high sensitivity is comparable to detection limits for 14C-labeled carcinogens using 14C AMS and demonstrates the feasibility of 3H AMS for biomedical studies. One application of this technique is in low-dose, dual-isotope studies in conjunction with 14C AMS. We measured the levels of 3H-labeled 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 14C-labeled 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in rat liver tissue and bound to liver DNA and protein 4.5 h following acute administration of individual or coadministered doses in the range of 4-5100 pmol/kg of body weight. Levels of PhIP and MeIQx in whole tissue and bound to liver protein were dose-dependent. MeIQx-protein and -DNA adduct levels were higher than PhIP adduct levels, which is consistent with their respective carcinogenicity in this organ. Coadministration of PhIP and MeIQx did not demonstrate any measurable synergistic effects compared to administration of these compounds individually. These studies demonstrate the application of AMS for the low-level detection of 3H in small biological samples and for its use in conjunction with 14C AMS for dual-labeling studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 030223242

Download citation: RISBibTeXText

PMID: 9778319

DOI: 10.1021/tx9801458


Related references

Biological carbon-14 and tritium-tracer studies with attomole sensitivity using accelerator mass spectrometry. Abstracts of Papers American Chemical Society 219(1-2): TOXI 106, 2000

Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metabolism and Pharmacokinetics 24(2): 130-138, 2009

Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range. Analytical Chemistry 86(15): 7635-7641, 2015

Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies. Analytical Chemistry 83(14): 5607-5616, 2012

Aluminum 26 tracer experiment by accelerator mass spectrometry and its application to the studies for amyotrophic lateral sclerosis and alzheimers disease i. Proceedings of the Japan Academy Series B Physical & Biological Sciences 66(10): 189-196, 1990

26Al tracer experiment by accelerator mass spectrometry and its application to the studies for amyotrophic lateral sclerosis and Alzheimer's disease. I. Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences 66(10): 189-192, 1990

Attomole quantitation of protein separations with accelerator mass spectrometry. Electrophoresis 22(10): 2037-2045, 2001

A phase I, open-label, single-dose micro tracer mass balance study of 14 C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry. Drug Metabolism and Pharmacokinetics 33(2): 118-124, 2018

Biomedical accelerator mass spectrometry for attomole sensitivity in drug bioanalysis. European Journal of Pharmaceutical Sciences 6(SUPPL 1): S14, 1998

Accelerator mass spectrometry of small biological samples. Rapid Communications in Mass Spectrometry 22(23): 3928-3934, 2008

Attomole level protein sequencing by Edman degradation coupled with accelerator mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America 98(8): 4403-4408, 2001

Biological and biomedical (14)C-accelerator mass spectrometry and graphitization of carbonaceous samples. Analyst 138(12): 3347-3355, 2013

Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry. Analytical Biochemistry 269(2): 348-352, 1999

Isolation of Pu-isotopes from environmental samples using ion chromatography for accelerator mass spectrometry and alpha spectrometry. Analytica Chimica Acta 606(2): 239-245, 2007

Multiactinide Analysis with Accelerator Mass Spectrometry for Ultratrace Determination in Small Samples: Application to an in Situ Radionuclide Tracer Test within the Colloid Formation and Migration Experiment at the Grimsel Test Site (Switzerland). Analytical Chemistry 89(13): 7182-7189, 2017